Bio-Techne has been granted a patent for mutant TcBuster transposases that exhibit increased transposition efficiency. These mutants have amino acid sequences at least 70% identical to a specified sequence and include substitutions that enhance their net charge at neutral pH. GlobalData’s report on Bio-Techne gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bio-Techne, Peptide pharmacophores was a key innovation area identified from patents. Bio-Techne's grant share as of June 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Mutant tcbuster transposase with increased transposition efficiency
The patent US12037611B2 describes a novel mutant TcBuster transposase characterized by an amino acid sequence that is at least 70% identical to the full-length sequence identified as SEQ ID NO: 1. This mutant transposase features one or more amino acid substitutions that enhance its net charge at neutral pH compared to the wild-type TcBuster transposase. Specific substitutions mentioned include D99A, E247K, and E469K, which contribute to increased transposition efficiency. The claims further detail that these substitutions can occur in various functional domains of the transposase, including DNA binding and oligomerization domains, as well as catalytic domains, thereby potentially improving its performance in genetic applications.
Additionally, the patent outlines a system for genome editing that incorporates the mutant TcBuster transposase along with a transposon that it can recognize. The claims also include the development of fusion transposases that combine the mutant TcBuster transposase with DNA sequence-specific binding domains, such as TALE or zinc finger domains. The methods described in the patent involve introducing the mutant transposase and a corresponding transposon into cells, including primary cells from subjects with cancer or tumors, to facilitate targeted genome editing. This innovative approach aims to enhance the efficiency and specificity of genetic modifications, which could have significant implications for therapeutic applications in gene therapy and biotechnology.
To know more about GlobalData’s detailed insights on Bio-Techne, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
